American Conference Institute: 14th Summit on Biosimilars & Innovator Biologics


Alice Chen, of the USC Sol Price School of Public Policy, will discuss the impact of the Inflation Reduction Act (IRA) at this annual event.

Professor Chen will speak on a panel titled, “The Inflation Reduction Act: Understanding the Impact on Biologic Innovation and the Biosimilar Marketplace.”

The Inflation Reduction Act (IRA) of 2022 aims to reduce inflation by decreasing the federal government budget deficit, cutting back prescription drug prices, and investing in energy production while incentivizing clean energy.

Participants will discuss the effects of the IRA on the biologics and biosimilars industries. Topics will include:

  • The IRA’s impact on innovation and R&D, as well as the economics of the biologic and biosimilars marketplaces
  • The IRA’s changes to reimbursement under Medicare Parts B and D
  • The proposed timeline from the Centers for Medicare & Medicaid Services (CMS) for inflation rebates on biologic-biosimilar products
  • Competition between new biologics and biosimilar drugs in the commercial marketplace outside of government payor programs

Cornerstone Research is a sponsor of this event, hosted by American Conference Institute (ACI). For more information, visit the event website.


Alice Chen

Associate Professor,
Sol Price School of Public Policy;
Senior Fellow,
Leonard D. Schaeffer Center for Health Policy and Economics,
University of Southern California